MedTrace Logo

Use of Repris Needle in Bladder Injection

NCT04982120 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2021-07-29

No results posted yet for this study

Summary

Treatment of overactive bladder (OAB) has been treated successfully by the injection of Botox. The Repris injection needle has a deflection that may assist in injection difficult to reach with standard straight needles. This study will assess the success, safety and patient tolerance of this new injection needle.

Conditions

  • Overactive Bladder Syndrome

Interventions

DEVICE

Repris Needle

Injection of Botox

Sponsors & Collaborators

  • Uro-1 Medical

    lead INDUSTRY

Principal Investigators

  • Thomas Lawson, PhD · Uro-1 Medical

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-10-15
Primary Completion
2022-06-14
Completion
2022-07-14
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04982120 on ClinicalTrials.gov